NASDAQ$MLYS
Mineralys Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Mineralys Therapeutics reported Q2 2025, net loss of $43.3M.
For Q2 2025, Mineralys Therapeutics reported a net loss of $43.3M. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Net loss $43.3M.
- Mineralys Therapeutics highlights operating priorities and capital allocation.
- Mineralys Therapeutics highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Mineralys Therapeutics · Revenue · Quarterly
$0
Forward guidance
The release discusses Mineralys Therapeutics's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Mineralys Therapeutics cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q2 2025.
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q2 2025
-1.0%
Avg return
Earnings day
-5.9%
Avg return
5 days after
+5.5%
Avg return
30 days after
53%
8 / 15 earnings
Positive
+10.0%
Q4 2024
Best reaction
-9.2%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.9% | -2.9% | -21.3% | |
| Q3 2025 | +5.9% | -8.2% | -19.0% | |
| Q2 2025 | +0.4% | +13.5% | +174.6% | |
| Q1 2025 | +2.6% | +4.8% | +6.1% | |
| Q4 2024 | +10.0% | +6.0% | +47.5% | |
| Q3 2024 | -4.7% | -18.2% | -7.8% | |
| Q1 2024 | -7.7% | -10.9% | -10.3% | |
| Q4 2023 | -4.1% | -4.1% | -15.7% | |
| Q3 2022 | +0.7% | -20.4% | -14.8% | |
| Q3 2023 | +0.7% | -20.4% | -14.8% | |
| Q2 2023 | +0.5% | -3.7% | -8.9% | |
| Q2 2022 | +0.5% | -3.7% | -8.9% | |
| Q1 2023 | -4.3% | -4.0% | -1.2% | |
| Q1 2022 | -4.3% | -4.0% | -1.2% | |
| Q4 2022 | -9.2% | -12.3% | -22.0% | |
| Q4 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro